Latest Actavis Inc (ACT) Headlines
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 56 mins ago
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.
Stocks Down 1% In Late Afternoon As Volume Picks Up
at Investor's Business Daily - Thu Mar 13, 2:54PM CDT
Stocks were down 1% or more late Thursday afternoon as ongoing worries about China and Ukraine trumped better-than-expected U.S. economic data. The Nasdaq slumped 1.4%, the Dow Jones industrial average lost 1.2%, with 28 of 30 issues lower. The S&P...
Is the Market Undervaluing Celgene?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 13, 1:30PM CDT
Celgene admittedly does not leap off the page as a cheap stock, at least not with a cursory glance. The shares are up about 40% over the past year (and more than 100% over the past two years) and trade at more than nine times sales and 11 times...
Narrower-than-Expected Loss at Supernus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:40AM CDT
Supernus reported 4Q13 net loss per share of 39 cents, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit
PR Newswire - Wed Mar 12, 4:35PM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid. Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for infringement of the '048 Patent in connection with its Abbreviated New Drug Application directed to Actavis' generic version of Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Greenberg: What You May Have Missed
at The Street - Wed Mar 12, 8:33AM CDT
What you may have missed, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers. It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red...
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
How To Invest: Seek Stock Ideas In Sector Leaders
at Investor's Business Daily - Tue Mar 11, 4:23PM CDT
Every great trade begins with a great idea. While there's a wealth of places in IBD to get great ideas for your watch list, one feature that investors must check out is Sector Leaders. Published today on Page B1, the Sector Leaders are the top-rated...
Stock Indexes Reverse Lower, But McDonald's Leaps 3%
at Investor's Business Daily - Tue Mar 11, 3:20PM CDT
Stocks staged a negative reversal Tuesday, turning a promising morning into a disappointing finish. The Nasdaq stumbled in late morning, eventually turning a 0.5% gain into a 0.6% loss. The S&P 500 and Dow Jones industrial average fell 0.5% and 0.4%,...
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (8) - Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (8) For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Forest Labs/Adamas Seek FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:00PM CST
Forest Labs/Adamas files NDA for fixed-dose combination of Namenda ER/Aricept
Is Mylan a Good Buy?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
As branded drugs have become more complicated and global growth has become more important to generic franchises, scale matters more than ever. That's a definite check mark in the plus column for Mylan , as it is among the largest generic drug...
Major Indexes Give Up Early Gains; Jazz, 58.com Rise
at Investor's Business Daily - Fri Mar 07, 11:12AM CST
The major averages gave up their early gains and were near session lows in midday trading Friday as investors digested employment data. The Nasdaq was down 0.4% and the S&P 500 fell fractionally. The Dow industrials edged 0.2% higher. Volume was...
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis
PR Newswire - Fri Mar 07, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Today’s 3 Worst Stocks in the S&P 500
John Divine, The Motley Fool - Motley Fool - Thu Mar 06, 6:22PM CST
The S&P 500 Index edged higher on Thursday, finishing at another all-time high, its fourth such record in the past six trading days. Fueling the bullishness were jobless claims, which came in lower than expected, giving Wall Street hope that...
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 56 mins ago
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.
Stocks Down 1% In Late Afternoon As Volume Picks Up
at Investor's Business Daily - Thu Mar 13, 2:54PM CDT
Stocks were down 1% or more late Thursday afternoon as ongoing worries about China and Ukraine trumped better-than-expected U.S. economic data. The Nasdaq slumped 1.4%, the Dow Jones industrial average lost 1.2%, with 28 of 30 issues lower. The S&P...
Is the Market Undervaluing Celgene?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 13, 1:30PM CDT
Celgene admittedly does not leap off the page as a cheap stock, at least not with a cursory glance. The shares are up about 40% over the past year (and more than 100% over the past two years) and trade at more than nine times sales and 11 times...
Narrower-than-Expected Loss at Supernus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:40AM CDT
Supernus reported 4Q13 net loss per share of 39 cents, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus
PR Newswire - Thu Mar 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), GW Pharmaceuticals plc (NASDAQ: GWPH), Galena Biopharma, Inc. (NASDAQ: GALE), and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit
PR Newswire - Wed Mar 12, 4:35PM CDT
Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the Eastern District of Virginia has ruled that United States Patent No. RE44,048 (the '048 Patent) is invalid. Actavis was earlier sued by Plaintiffs G.D. Searle LLC and Pfizer Asia Pacific PTE, Ltd. for infringement of the '048 Patent in connection with its Abbreviated New Drug Application directed to Actavis' generic version of Pfizer's Celebrex® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Pfizer Loses Patent On Celebrex, Plans To Appeal
at Investor's Business Daily - Wed Mar 12, 2:59PM CDT
Big pharma Pfizer (PFE) briefly halted trading Wednesday afternoon to announce that a patent on best-selling arthritis drug Celebrex had been invalidated by a district court. When trading resumed, shares were down nearly 1% in the stock market today....
Greenberg: What You May Have Missed
at The Street - Wed Mar 12, 8:33AM CDT
What you may have missed, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers. It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red...
Will Horizon Pharma Spike Again On Quarterly Report?
at Investor's Business Daily - Wed Mar 12, 7:02AM CDT
Shares of small specialty drug company Horizon Pharma (HZNP) have been on the move since it reported third-quarter results in early November, thanks to expectations for the firm's novel drugs that treat arthritis, pain and inflammatory conditions....
How To Invest: Seek Stock Ideas In Sector Leaders
at Investor's Business Daily - Tue Mar 11, 4:23PM CDT
Every great trade begins with a great idea. While there's a wealth of places in IBD to get great ideas for your watch list, one feature that investors must check out is Sector Leaders. Published today on Page B1, the Sector Leaders are the top-rated...
Stock Indexes Reverse Lower, But McDonald's Leaps 3%
at Investor's Business Daily - Tue Mar 11, 3:20PM CDT
Stocks staged a negative reversal Tuesday, turning a promising morning into a disappointing finish. The Nasdaq stumbled in late morning, eventually turning a 0.5% gain into a 0.6% loss. The S&P 500 and Dow Jones industrial average fell 0.5% and 0.4%,...
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (8) - Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (8) For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Forest Labs/Adamas Seek FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:00PM CST
Forest Labs/Adamas files NDA for fixed-dose combination of Namenda ER/Aricept
Is Mylan a Good Buy?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
As branded drugs have become more complicated and global growth has become more important to generic franchises, scale matters more than ever. That's a definite check mark in the plus column for Mylan , as it is among the largest generic drug...
Major Indexes Give Up Early Gains; Jazz, 58.com Rise
at Investor's Business Daily - Fri Mar 07, 11:12AM CST
The major averages gave up their early gains and were near session lows in midday trading Friday as investors digested employment data. The Nasdaq was down 0.4% and the S&P 500 fell fractionally. The Dow industrials edged 0.2% higher. Volume was...
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis
PR Newswire - Fri Mar 07, 5:50AM CST
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that the Company has repurchased 1.4 million shares of its common stock, par value $0.01 per share, from Coventry Acquisition, LLC, a subsidiary of Actavis Inc. (Actavis), at $6.08 per share, which represents a 10.75% discount to the closing price on Thursday, March 6, 2014. The total purchase price was approximately $8.5 million. This transaction reduces the total issued and outstanding shares of common stock by about 11.5% from approximately 12.15 million to 10.75 million.
Today’s 3 Worst Stocks in the S&P 500
John Divine, The Motley Fool - Motley Fool - Thu Mar 06, 6:22PM CST
The S&P 500 Index edged higher on Thursday, finishing at another all-time high, its fourth such record in the past six trading days. Fueling the bullishness were jobless claims, which came in lower than expected, giving Wall Street hope that...
